CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02601950
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:40.066980+00:00
Published At: 2025-03-11T00:00:00+00:00
Record Updated At: 2025-06-22
Results Posted At: 2025-03-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Rhabdoid Tumors (MRT)", "Rhabdoid Tumors of the Kidney (RTK)", "Atypical Teratoid Rhabdoid Tumors (ATRT)", "Selected Tumors With Rhabdoid Features", "Synovial Sarcoma", "INI1-negative Tumors", "Malignant Rhabdoid Tumor of Ovary", "Renal Medullary Carcinoma", "Epithelioid Sarcoma", "Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)", "Any Solid Tumor With an EZH2 GOF Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-22"
protocolSection.identificationModule.nctId: "NCT02601950"
protocolSection.identificationModule.officialTitle: "A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-03-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.